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Drug-resistant tuberculosis threatens to undermine global control programs by limiting
treatment options. New antimicrobial drugs are required, derived from new chemical
classes. Natural products offer extensive chemical diversity and inspiration for
synthetic chemistry. Here, we isolate, synthesize and test a library of 52 natural and
synthetic compounds for activity against Mycobacterium tuberculosis. We identify seven
compounds as antimycobacterial, including the natural products isobavachalcone and
isoneorautenol, and a synthetic chromene. The plant-derived secondary metabolite
damnacanthal was the most active compound with the lowest minimum inhibitory
concentration of 13.07 µg/mL and a favorable selectivity index value. Three synthetic
polyacetylene compounds demonstrated antimycobacterial activity, with the lowest MIC
of 17.88 µg/mL. These results suggest new avenues for drug discovery, expanding
antimicrobial compound chemistries to novel anthraquinone and polyacetylene scaffolds
in the search for new drugs to treat drug-resistant bacterial diseases.
Keywords: Mycobacterium tuberculosis, drug discovery, natural product, synthetic polyacetylenes, antimicrobial
drug resistance
INTRODUCTION
Tuberculosis (TB) is an infectious disease that is among the top 10 causes of death worldwide, and
the leading bacterial cause of death. In 2019, an estimated 10 million people developed TB and
1.4 million people died as result of the disease (World Health Organization, 2020). TB treatment
requires the use of multiple drugs for at least 6 months. This lengthy therapy together with
adverse drug reactions contribute to patient non-adherence, resulting in treatment failure and the
development of drug-resistant Mycobacterium tuberculosis. The emergence of multidrug-resistant
(MDR) TB and extensively drug resistant (XDR) TB is undermining global control efforts. In 2019,
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3.3% of new TB cases and 17.7% of previously treated cases were
rifampicin-resistant (RR)/MDR-TB. There were an estimated
465,000 incident cases of RR-TB in the same year, of which 78%
were MDR-TB (World Health Organization, 2020). Therefore,
there is an urgent need, recognized by the World Health
Organization (World Health Organization, 2014), for new drugs
to treat drug-resistant TB, and to shorten therapy for drug-
sensitive TB. However, despite sustained international efforts,
only pretomanid, delamanid and bedaquiline have been marketed
as new drugs for TB treatment in the last 40 years (The Working
Group for New TB Drugs, 2020). Intensified research and
innovation are needed to meet the End TB Strategy targets set
for 2030, a key priority of which is to discover new drugs based
on new chemical entities (World Health Organization, 2014).
Over the past 60,000 years, plant-derived medicines have
been used as decoctions, infusions and tinctures to improve
human health (Solecki and Shanidar, 1975). Numerous studies
have attempted to correlate ethnological knowledge with the
scientific evidence base (De Smet, 1997). Natural products
are an essential source of biologically active components
(Thomford et al., 2018; Wright, 2019), and naturally occurring
secondary metabolites have inspired the development of
therapeutic drugs for infectious, cardiovascular, and degenerative
diseases (Thomford et al., 2018; Lautié et al., 2020). Natural
products are composed of numerous structural diversities,
often containing complex hydrocarbon skeletons that have
been explored to produce libraries of biologically relevant
derivatives (Salomon and Schmidt, 2012; Pascolutti and
Quinn, 2014). Dorstenia plant species are used in sub-Saharan
African and South American countries as herbal medicines
to treat cough, pneumonia and other infectious diseases
such as malaria, syphilis, and hepatitis (Togola et al., 2008;
Teklehaymanot, 2009; Bieski et al., 2012; Adem et al., 2018).
Prenylated flavonoids obtained from Dorstenia species showed
antibacterial activity against a broad-spectrum of bacteria,
including M. tuberculosis (Mbaveng et al., 2012). Secondary
metabolites from Erythrina senegalensis, the Senegal coral
tree, have been demonstrated to exhibit strong inhibition
of methicillin resistant Staphylococcus aureus, Enterococcus
faecalis, and Bacillus subtilis (Koné et al., 2004). Damnacanthal,
an anthraquinone obtained from Pentas schimperi, displayed
moderate activity against the Trypanosoma cruzi amastigote
(Sandjo et al., 2016b). As numerous biologically active molecules
have been inspired by the organic constituents of plants, our
group prepared a series of pyridine and chromene derivatives
(Pollo et al., 2017; Martin et al., 2018). These compounds were
evaluated for their antiparasitic activities against Leishmania
amazonensis and T. cruzi amastigotes. Three pyridines and
three chromenes inhibited T. cruzi with IC50 values less than
7 µM. Similarly, a coumarin scaffold was used to generate
anti-TB agents, while polyacetylenes from plants and pyridine
derivatives have been shown to express antimycobacterial
activities (Rogoza et al., 2010; Somagond et al., 2019; Kumar
et al., 2020).
Here, we report the extraction, synthesis, and anti-
M. tuberculosis activity of 52 compounds: six plant secondary
metabolites from Dorstenia kameruniana, Dorstenia mannii,
P. schimperi, and E. senegalensis, and 46 synthetic compounds
including 20 dihydropyridines, 12 pyranocoumarins, seven
chromenes, one oxazinone, one conjugated ester and five
polyacetylenes. This study identifies anthraquinone and
polyacetylene compounds as the basis for novel drug discovery
toward new therapeutic options for drug-resistant TB.
MATERIALS AND METHODS
Origin of the Natural Products
Isobavachalcone (C1) was isolated from D. kameruniana, while 4-
hydroxylonchocarpine (C21) and 6,8-diprenyleriodictyol (C24)
were obtained from D. mannii (Abegaz et al., 1998; Ngadjui
et al., 1998). Damnacanthal (C22) and its reduced derivative
(C25) were isolated from P. schimperi (Kuete et al., 2015a).
Isoneorautenol (C23) was extracted from E. senegalensis (Kuete
et al., 2014). The structures of these natural secondary metabolites
are displayed in Figures 1, 2.
Preparation of the Pyranocoumarin
Derivatives
Compound 50 (C50) was synthesized by treating phloroglucinol
at 60◦C for 6 h with one equivalent of ethyl acetoacetate
and a catalytic amount of polyphosphoric acid. This coumarin
was then used as the starting material to prepare a series of
pyranocoumarins. C50, arylaldehydes, malononitrile, and K2CO3
were submitted to reflux conditions to generate compounds
C2–C7. Compounds C8–C12 were obtained using the same
one-pot conditions except that malononitrile was replaced by
methyl α-cyanoacetate. C13 was a by-product formed from the
Knoevenagel condensation reaction of cinnamaldehyde and α-
cyanoacetate in the same reaction conditions. The structures are
detailed in Figures 1, 2, 4 (Martin et al., 2018).
Preparation of Chromenes
Chromene derivatives C14–C20 were obtained by a direct
reaction of phloroglucinol, arylaldehydes and methyl α-
cyanoacetate in alkaline reflux conditions. We have previously
described the synthesis and the identification of C2–C20 (Martin
et al., 2018), shown in Figure 2.
Preparation of Dihydropyridine
Derivatives and Analogs
Bismuth chloride was used to promote the reaction, which
was carried out in tetrahydrofuran under reflux conditions
and was stirred for 6 h to synthesize compounds C29–C33
(Sandjo et al., 2016a). C34–C41 were obtained from the same
reaction conditions replacing ethyl benzoylacetate with ethyl
acetylacetate in reflux and free catalyst conditions to prepare
these dihydropyridine analogs. C42–C49 were also synthesized
in reflux conditions without any catalyst, replacing ammonium
acetate with aniline. The preparation of these dihydropyridine
analogs has been described (Pollo et al., 2017), and their
structures are displayed in Figures 3, 4.
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FIGURE 1 | Structures of the compounds tested for anti-M. tuberculosis activity: Chalcone C1, and the pyranocoumarins C2–C12 (Abegaz et al., 1998; Martin et al.,
2018).
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FIGURE 2 | Structures of the compounds tested for anti-M. tuberculosis activity: Ester C13, chromenes C14–C20, and natural products C21–C25 (Ngadjui et al.,
1998; Kuete et al., 2014, 2015a; Martin et al., 2018).
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FIGURE 3 | Structures of the compounds tested for anti-M. tuberculosis activity: Dihydropyridines C29–C44 (Sandjo et al., 2016a; Pollo et al., 2017).
Preparation of the Polyacetylene
Derivatives
Deca-4,6,8-triyn-1-ol (C51), deca-4,6,8-triynal (C52),
7-(triisopropylsilyl)hepta-4,6-diyn-1-ol (C54) and 9-
(triisopropylsilyl)nona-4, 6-,8-triyn-1-ol (C55) were previously
synthesized, identified and reported by Machado and co-workers
(Machado et al., 2018). Tetradeca-4,6,8,10-tetrayne-1,14-diol
(C53) was prepared by homodimerization reaction in a 25 mL,
two neck, round-bottom flask equipped with rubber septum and
a magnetic stir bar, filled with a solution of hepta-4,6-diyn-1-ol
(0.1 g; 0.925 mmol; 1 equiv.) in CH3CN (10 mL). To this solution
was added Cu(OAc)2 (0.353 g; 1.94 mmol; 2.1 equiv) and K2CO3
(0.153 g; 1.11 mmol; 1.2 equiv. The resulting mixture was stirred
vigorously at room temperature overnight (∼18 h). The organic
extract was washed with brine (20 mL), dried over MgSO4,
filtered, and concentrated under reduced pressure. Purification
by column chromatography on silica gel (elution with 40%
EtOAc-hexanes) afforded 0.063 g (32 %) of tetradeca-4,6,8,10-
tetrayne-1,14-diol as a pale yellow oil. mp 116.5 - 117◦C; R.f :
0.75 (40% hexane-ethyl acetate; 1H NMR (300 MHz, CD3OD)
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FIGURE 4 | Structures of the compounds tested for anti-M. tuberculosis activity: Dihydropyridines C45–C49, coumarin C50, and polyacetylenes C51–C55 (Sandjo
et al., 2016a; Pollo et al., 2017; Machado et al., 2018; Martin et al., 2018).
δ in ppm: 3.61(t, 4H), 2.44 (t, J=7.15 Hz, 4H), 1.74 (m, 4H).
13C-NMR (75 MHz, CD3OD) δ in ppm: 81.4; 66.1; 62.1; 61.2;
60.8; 31.9; 16.5. The structures of these compounds are shown
in Figure 4.
Bacteria and Culture Conditions
Mycobacterium tuberculosis H37Rv reference strain was cultured
in Middlebrook 7H9 broth (Sigma-Aldrich) supplemented
with albumin dextrose catalase (ADC, 10% v/v) and Tween
80 (0.05% v/v) at 37◦C. Optical density was measured
using a spectrophotometer (Promega) at absorbance 600 nm.
Colony forming units (CFU) were determined by serially
diluting cultures onto Middlebrook 7H10 agar (Sigma-Aldrich)
supplemented with 0.5% glycerol and oleic acid albumin dextrose
catalase (OADC, 10% v/v) and incubated at 37◦C for 4 weeks. All
M. tuberculosis work was conducted in containment level three
laboratories, following institutional biosafety and biosecurity
standards for working with hazard group three pathogens.
Antimycobacterial Activity
All compounds were prepared as 10 mg/mL stock solutions
in sterile dimethyl sulfoxide (DMSO), except for rifampicin
which was prepared with 90% w/v methanol. Single use aliquots
of compounds were prepared and stored at −20◦C. Log
phase M. tuberculosis cultures were adjusted from 2 × 105 to
5 × 105 CFU/mL, added to 96 well microtiter plates containing
test compounds at a final concentration of 100 µg/mL (1%
DMSO final concentration), and incubated for 7 days at 37◦C.
To determine cell viability, CellTiter-Blue (Promega) was
added to the plates at a final concentration of 10% v/v and
incubated overnight (Franzblau et al., 1998). Fluorescence was
measured at excitation 580–640 nm and emission 520 nm
using a Glomax Discover plate reader (Promega). Hits were
classified as any compound that inhibited growth by ≥40%
compared to drug-free M. tuberculosis controls. This cut-off
was selected to capture the range of antimicrobial activity of
related chemical compounds, rather than highlight individual
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FIGURE 5 | Compound library screen against Mycobacterium tuberculosis. Log phase M. tuberculosis was treated with compounds at 100 µg/mL for 7 days,
bacterial survival was measured after overnight incubation with CellTiter-Blue. Data points are expressed as mean % survival compared to drug-free controls. Error
bars represent the standard deviation. Hits were classified as any compound that inhibited growth by ≥40%. Filled circles identify hit compounds. Empty circles
indicate compounds not classified as hits. The mean bacterial survival ≤60% shown as a dotted line. Filled triangle (RIF) marks rifampicin-treated bacilli. Empty
square (PC) indicates drug-free positive controls.
compounds with superior activity. Minimum inhibitory
concentrations (MIC) of hit compounds were determined using
a resazurin microtiter plate assay (REMA) with CellTiter-Blue
(Promega) as described above, with two-fold serial dilutions from
100 µg/mL to 1.56 µg/mL. The MIC experiments were repeated
in triplicate. MICs were calculated by non-linear regression,
fitting these data to a modified Gompertz equation for MIC
determination, using GraphPad Prism 8. Validation of this assay
for established TB drugs (isoniazid and linezolid) is detailed in
Supplementary Figure 1.
Cytotoxicity Assay
The human monocytic THP-1 cell line was maintained at
37◦C, 5% CO2 in supplemented RPMI 1640 medium (Gibco,
Life Technologies) containing 2 mM L-glutamine (Gibco, Life
Technologies) and 10% heat inactivated FBS (Pan Biotech).
The cells were passaged every 4 days. To measure compound
cytotoxicity, 5 × 104 monocytes per well were added to 96 well
plates and treated for 24 h with the compounds at concentrations
ranging from 200 µg/mL to 1.56 µg/mL. Cell viability was
determined by fluorescence quantification after 2 h incubation
with CellTiter-Blue (Promega), according to the manufacturer’s
instructions. Fluorescence was measured at excitation 580–
640 nm and emission 520 nm using a Glomax Discover plate
reader (Promega). Fluorescence values were adjusted for media
fluorescence and the inhibitory concentration 50% (IC50) was
calculated using Graphpad Prism 8. The selectivity index (SI)
of each compound was calculated by dividing the IC50 by the
corresponding M. tuberculosis MIC value.
RESULTS AND DISCUSSION
The discovery of biologically active new chemical entities is
crucial to developing novel chemotherapeutic agents against
drug resistant bacterial infections, including TB. Chemistry
uses synthetic approaches and analytic techniques to identify
and isolate natural products and to produce small molecules
bearing diverse hydrocarbon skeletons for preclinical studies
(Lombardino and Lowe, 2004; Campbell et al., 2018). To
contribute to the search for new anti-tubercular agents, a
library of 52 natural and synthetic compounds (Figures 1–4)
were tested against log phase M. tuberculosis. The library
contained compounds with diverse chemistries including 11
pyranocoumarins (C2–C12), seven chromenes (C14–C20), one
conjugated arylester (C13), two chalcones (C1 and C21), two
anthraquinones (C22 and C25), one pterocarpan (C23), one
flavanone (C24), 20 dihydropyridines (C29–C32 and C34–
C49), one oxazinone (C33), one coumarin (C50), and five
polyacetylenes (C51–C55).
Antimycobacterial Activity
The initial screen of the compound library at 100 µg/mL, using
the colorimetric CellTiter-Blue assay to measure mycobacterial
viability, identified 17 of the 52 compounds that inhibited
M. tuberculosis survival by at least 40% in comparison to drug-
free bacilli (Figure 5). Five compounds inhibited M. tuberculosis
at a level similar to the first line anti-TB drug rifampicin.
To verify the results of the initial screen and to establish
compound activity, minimum inhibitory concentrations (MICs)
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FIGURE 6 | Dose response curves of Mycobacterium tuberculosis treated with hit compounds. M. tuberculosis was treated for 7 days with compounds ranging in
concentration from 100 µg/mL to 1.56 µg/mL. Bacterial survival was measured after overnight incubation with CellTiter-Blue to establish minimum inhibitory
concentrations (MICs). Data points are expressed as mean % survival relative to drug-free controls from duplicate biological replicates. Error bars represent the
standard deviation.
were determined for all 17 hits using the microbroth dilution
method. Compound C22 (the natural product damnacanthal)
displayed the greatest activity, with a MIC of 13.07 µg/mL,
followed by the polyacetylene C53 with a MIC of 17.88 µg/mL
(Figure 6 and Table 1). Compounds C1, C10, C23, C51, and
C52 were demonstrated to have MICs against M. tuberculosis
between 25 and 71 µg/mL (Figure 6 and Table 1). Compounds
C13, C14, C15, C24, C36, C38, C40, C41, C45, and C49 resulted in
MICs ≥100 µg/mL. Thus, we identified seven chemically diverse
compounds that inhibited M. tuberculosis.
The top hit against M. tuberculosis was damnacanthal (C22 –
MIC of 13.07 µg/mL), a naturally occurring secondary metabolite
isolated from the tropical plant P. schimperi (Figure 6),
which has previously been demonstrated to have antibacterial
activity against S. aureus and Pseudomonas aeruginosa. Further
investigation revealed that its inhibitory effect on S. aureus
might be related to an increase in toxic reactive oxygen
species (Comini et al., 2011). This natural metabolite has
also been demonstrated to have prominent antifungal activity
against Aspergillus ochraceus, Aspergillus niger and Candida
lipolytica (Ali et al., 2000). It also displayed anti-parasitic
properties against T. cruzi amastigotes (Sandjo et al., 2016b).
The antimycobacterial activity of damnacanthal (C22) is likely
linked to its aldehyde functional group as compound C25
(rubiadin 1-methyl ether), its reduced form, showed no anti-
M. tuberculosis activity.
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TABLE 1 | Antimycobacterial and cytotoxic activities of hit compounds against
Mycobacterium tuberculosis.
Compound MIC (µg/mL) IC50 (µg/mL) Selectivity index
C1 51.77 45.85 0.89
C10 29.13 64.18 2.20
C13 105.6 95.94 0.91
C14 105.4 47.22 0.45
C15 >100 N/D N/A
C22 13.07 21.41 1.64
C23 49.22 44.27 0.90
C24 >100 N/D N/A
C36 >100 N/D N/A
C38 >100 N/D N/A
C40 >100 N/D N/A
C41 >100 N/D N/A
C45 >100 N/D N/A
C49 >100 N/D N/A
C51 70.69 170.5 2.41
C52 50.58 N/D* N/A
C53 17.88 17.00 0.95
Detailing MIC, IC50, and selectivity index values. MIC, minimum inhibitory
concentration against M. tuberculosis; IC50, inhibitory concentration 50% for
human monocyte THP-1 cells; N/D, not done; N/A, not applicable. *IC50 for C52
was not conducted due to compound degradation over time.
The dimeric polyacetylene C53 (tetradeca-4,6,8,10-tetrayne-
1,14-diol) was the second most active compound against
M. tuberculosis, with a MIC of 17.88 µg/mL. Several
naturally occurring polyacetylene alcohols with acyclic
hydrocarbon backbones have been reported with moderate
to significant antimycobacterial activity against Mycobacterium
fortuitum, Mycobacterium avium, Mycobacterium aurum, and
M. tuberculosis H37Ra (Kobaisy et al., 1997; Schinkovitz et al.,
2008; Haoxin et al., 2012). These metabolites also showed a wide
spectrum of antibacterial action against Gram positive bacteria
(S. aureus and B. subtilis), Gram negative bacteria (Escherichia
coli and P. aeruginosa), Candida albicans, M. tuberculosis, and
isoniazid-resistant M. avium (Kobaisy et al., 1997; Christensen,
2011), supporting the antimicrobial activity presented here using
a synthetic polyacetylene. Other synthetic polyacetylenes of the
series tested (C51 and C52) were active against M. tuberculosis
(Figure 6), while C54 and C55 were not. C52 was more active
than C51, with MICs of 50.58 µg/mL and 70.69 µg/mL,
respectively, and both compounds differ from each other by
the hybridization of atoms in the C-O bond. C53, obtained
from the homodimerization of C51, showed the highest anti-
M. tuberculosis activity among the polyacetylenes, suggesting
that the observed bioactivity might be promoted by the high
conjugated π-electron system.
The natural product isobavachalcone (C1), isolated from
D. kameruniana, was moderately inhibitory to M. tuberculosis
with a MIC of 51.77 µg/mL (Figure 6). This compound has
been previously determined to be active against M. tuberculosis
(Chiang et al., 2010), verifying our library screen. Antibacterial
activity against both Gram positive and Gram negative bacteria
(Mbaveng et al., 2008) has also been observed, alongside
antifungal activity, inhibiting C. albicans (ElSohly et al., 2001).
Prenylated chalcones structurally close to isobavachalcone have
also been identified as broad-spectrum antibacterial agents
(Sugamoto et al., 2011). Isoneorautenol (C23), a natural
secondary metabolite isolated from E. senegalensis, had a MIC
of 49.22 µg/mL against M. tuberculosis (Figure 6), and has also
been shown to inhibit growth of the fast-growing non-pathogenic
Mycobacterium smegmatis and Gram negative bacteria (Mitscher
et al., 1988; Mbaveng et al., 2015). Of note, the natural product 4-
hydroxylonchocarpine (C21), a flavonoid class chalcone isolated
from D. mannii, was not mycobactericidal despite previous
reports of antibacterial activity (Kuete et al., 2013).
The synthetic chromene C10 showed good antimycobacterial
activity with a MIC of 29.13 µg/mL against M. tuberculosis
(Figure 6). This compound, prepared for a previous study,
demonstrated anti-parasitic action against both T. cruzi and
L. amazonensis (Martin et al., 2018). Chromene derivatives
bearing trisubstituted amines were previously reported as
antimycobacterial against M. tuberculosis H37Rv (Raj and
Lee, 2020). C10, the most active compound among the
pyranocoumarin derivatives, differs from the others with the
substituent group on the aryl moiety and the ester function on
the pyran ring. C16, different from C10 by the coumarin ring,
was not active against M. tuberculosis. However, when the NO2
group in C16 was replaced by the halogen atom (compound C14),
a weak antimycobacterial activity was observed (Figure 6). C13
also contains a high conjugated π-electron system, although not
as linear as in the C53 structure, which might support the weak
activity of this compound against M. tuberculosis (Figure 6).
Compound Toxicity
Compounds that exhibited significant antimycobacterial activity
were assessed for toxicity toward human monocytic (THP-1)
cells in vitro, and the IC50 and selectivity index (SI) values were
calculated for each compound. Compounds C1, C13, C14, C23,
and C53 exhibited SI values lower than 1, while compounds C10,
C22, and C51 exhibited SI values greater than 1, but limited to a
maximum of 2.41 (Table 1). Therefore, efforts will be required to
improve the selectivity of these compounds for mycobacteria.
Several of these compounds have been previously described
to have moderate to low cytotoxicity to healthy cells. During
evaluation of isobavachalcone (C1) on intracellular parasites,
C1 showed some toxicity to THP-1 cells with a cytotoxic
concentration 50% (CC50) of 11.65 µg/mL. Compound C22 in
the same study inhibited the growth of THP-1 cells with a CC50 of
8.87 µg/mL (Sandjo et al., 2016b). Compounds C13 and C14 were
also identified to be moderately toxic to human monocyte cells
alongside their intracellular antiprotozoal activity (Martin et al.,
2018), correlating with our findings here. Isoneorautenol (C23)
was reported as antiproliferative without showing cytotoxicity to
AML12 hepatocytes at concentrations up to 123.46 µM (Kuete
et al., 2014; Kuete et al., 2015b). No cytotoxicity studies have been
performed on the polyacetylenes (C51–C53). The intermediate
MIC values for these compounds against M. tuberculosis (as
shown in this study) are close to the IC50 values, resulting in
greater potential for cytotoxicity. The reduction of this toxicity
should be a priority for further compound development.
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CONCLUSION
New drugs are required to treat drug-resistant TB and the
rising threat of antimicrobial drug resistance (AMR). Natural
products, and synthetic compounds derived and inspired by
natural products, offer an extensive diversity of bioactive
chemical structures for drug discovery. Natural product screens
offer the opportunity to identify new chemical entities, with
likely novel modes of action to overcome existing bacterial
drug resistance mechanisms. Here, we report the anti-TB
activity of 52 natural and synthetic compounds selected to
have different hydrocarbon scaffolds and reported antimicrobial
or antiparasitic activities. We identify two compounds (C22
damnacanthal, and the dimeric polyacetylene C53) with MIC
values <20 µg/mL against M. tuberculosis, and five with MIC
values between 25 and 71 µg/mL. The synthetic chromene
C10 and polyacetylene C51 with moderate antimycobacterial
activity displayed low toxicity compared to the other active
compounds. This study suggests that the anthraquinone
damnacanthal (C22) and synthetic polyacetylenes (C53, C52,
and C51) deserve further chemical investigation as novel
antimycobacterial scaffolds, and biological experimentation
to elucidate mechanism of action in the search for new
antimicrobial drugs.
DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included
in the article/Supplementary Material, further inquiries can be
directed to the corresponding author/s.
AUTHOR CONTRIBUTIONS
LP, EM, VM, MLB, MWB, and LS conducted the compound
isolation, synthesis, and characterization. DC, LW, and SW
conducted the antimicrobial activity and cytotoxicity work. DC,
LW, SW, and LS wrote the manuscript. All authors contributed
to the design of the experiments and reviewed the manuscript.
FUNDING
Brazilian authors would like to thank CNPq and CAPES
for their financial support through the post-graduation
program. SW, LW, and DC acknowledge funding from
the Wellcome Trust Institutional Strategic Support Fund
(204833/Z/16/A) and (204538/Z/16/Z), and the University of
Brighton Santander Travel Award.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fmicb.
2020.622629/full#supplementary-material
Supplementary Figure 1 | Dose response curves of M. tuberculosis treated with
isoniazid or linezolid. M. tuberculosis was treated for 7 days with drug
concentrations ranging from 200 µg/mL to 0.09 µg/mL, in three-fold serial
dilutions. Bacterial survival was measured after overnight incubation with
CellTiter-Blue to establish minimum inhibitory concentrations (MICs). Data points
are expressed as mean % survival relative to drug-free controls from duplicate
biological replicates. Error bars represent the standard deviation.
REFERENCES
Abegaz, B. M., Ngadjui, B. T., Dongo, E., and Tamboue, H. (1998).
Prenylated chalcones and flavones from the leaves of Dorstenia kameruniana.
Phytochemistry 49, 1147–1150. doi: 10.1016/S0031-9422(98)00061-2
Adem, F. A., Kuete, V., Mbaveng, A. T., Heydenreich, M., Ndakala, A., Inguru,
B., et al. (2018). Cytotoxic benzylbenzofuran derivatives from Dorstenia
kameruniana. Fitoterapia 128, 26–30. doi: 10.1016/j.fitote.2018.04.019
Ali, A. M., Ismail, N. H., Mackeen, M. M., Yazan, L. S., Mohamed, S. M., Ho,
A. S. H., et al. (2000). Antiviral, cytotoxic and antimicrobial activities of
anthraquinones isolated from the roots of Morinda elliptica. Pharm Biol. 38,
298–301. doi: 10.1076/1388-0209(200009)3841-AFT298
Bieski, I. G. C., Santos, F. R., Oliveira, R. M., Espinosa, M. M., Macedo, M.,
Albuquerque, U. P., et al. (2012). Ethnopharmacology of medicinal plants of
the pantanal region (Mato Grosso, Brazil). Evid. Based Comp. Altern. Med. 2012,
1–36. doi: 10.1155/2012/272749
Campbell, I. B., Macdonald, S. J. F., and Procopiou, P. A. (2018). Medicinal
chemistry in drug discovery in big pharma: past, present and future. Drug
Discov. Today 23, 219–234. doi: 10.1016/j.drudis.2017.10.007
Chiang, C. C., Cheng, M. J., Peng, C. F., Huang, H. Y., and Chen, I. S. (2010).
A novel dimeric coumarin analog and antimycobacterial constituents from
Fatoua pilosa. Chem. Biodiversity. 7, 1728–1736. doi: 10.1002/cbdv.200900326
Christensen, L. P. (2011). Aliphatic C17-polyacetylenes of the falcarinol type as
potential health promoting compounds in food plants of the Apiaceae family.
Recent Pat. Food Nutr. Agric. 3, 64–77. doi: 10.2174/2212798411103010064
Comini, L. R., Montoya, S. C. N., Páez, P. L., Argüello, G. A., Albesa, I., and
Cabrera, J. L. (2011). Antibacterial activity of anthraquinone derivatives from
Heterophyllaea pustulata (Rubiaceae). J. PhotochemPhotobiol. B 102, 108–114.
doi: 10.1016/j.jphotobiol.2010.09.009
De Smet, P. A. (1997). Role of plant-derived drugs and herbal medicines in
healthcare. Drugs 54, 801–840. doi: 10.2165/00003495-199754060-00003
ElSohly, H. N., Joshi, A. S., Nimrod, A. C., Walker, L. A., and Clark, A. M.
(2001). Antifungal chalcones from Maclura tinctoria. Planta Med. 67, 87–89.
doi: 10.1055/s-2001-10621
Franzblau, S. G., Witzig, R. S., McLaughlin, J. C., Torres, P., Madico, G., Hernandez,
A., et al. (1998). Rapid, low-technology MIC determination with clinical
Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay.
J. Clin. Microbiol. 36, 362–366. doi: 10.1128/JCM.36.2.362-366.1998
Haoxin, L., O’Neill, T., Webster, D., Johnson, J. A., and Gray, C. A. (2012). Anti-
mycobacterial diynes from the Canadian medicinal plant Aralia nudicaulis.
J. Ethnopharmacol. 140, 141–144. doi: 10.1016/j.jep.2011.12.048
Kobaisy, M., Abramowski, Z., Lermer, L., Saxena, G., Hancock, R. E. W.,
and Towers, G. H. N. (1997). Antimycobacterial polyynes of Devil’s Club
(Oplopanax horridus), a North American native medicinal plant. J. Nat. Prod.
60, 1210–1213. doi: 10.1021/np970182j
Koné, W. M., Antindehou, K. K., Terreaux, C., Hostettmann, K., Traoré, D., and
Dosso, M. (2004). Traditional medicine in North Cote-d’Ivoire: screening of
50 medicinal plants for antibacterial activity. J. Ethnopharmacol. 93, 43–49.
doi: 10.1016/j.jep.2004.03.006
Kuete, V., Donfack, A. R. N., Mbaveng, A. T., Zeino, M., Tane, P., and Efferth,
T. (2015a). Cytotoxicity of anthraquinones from the roots of Pentas schimperi
towards multi-factorial drug-resistant cancer cells. Invest. New Drugs 33, 861–
869. doi: 10.1007/s10637-015-0268-9
Kuete, V., Mbaveng, A. T., Zeino, M., Fozing, C. D., Ngameni, B., Kapche, G. D.,
et al. (2015b). Cytotoxicity of three naturally occurring flavonoid derived
compounds (artocarpesin, cycloartocarpesin and isobavachalcone) towards
multi-factorial drug-resistant cancer cells. Phytomedicine 22, 1096–1102. doi:
10.1016/j.phymed.2015.07.006
Frontiers in Microbiology | www.frontiersin.org 10 January 2021 | Volume 11 | Article 622629
fmicb-11-622629 January 12, 2021 Time: 16:26 # 11
Pollo et al. Anthraquinone and Polyacetylenes Inhibit Mtb
Kuete, V., Noumedem, J. A., and Nana, F. (2013). Chemistry and pharmacology
of 4-hydroxylonchocarpin: a review. Chin. J. Integr. Med. 19, 475–480. doi:
10.1007/s11655-013-1195-7
Kuete, V., Sandjo, L. P., Kwamou, G. M., Wiench, B., Nkengfack, A. E., and Efferth,
T. (2014). Activity of three cytotoxic isoflavonoids from Erythrina excelsa and
Erythrina senegalensis (neobavaisoflavone, sigmoidin H and isoneorautenol)
toward multi-factorial drug resistant cancer cells. Phytomedicine 21, 682–688.
doi: 10.1016/j.phymed.2013.10.017
Kumar, G., Krishna, V. S., Sriram, D., and Jachak, S. M. (2020). Pyrazole–coumarin
and pyrazole–quinoline chalcones as potential antitubercular agents. Arch.
Pharm. 353, 1–14. doi: 10.1002/ardp.202000077
Lautié, E., Russo, O., Ducrot, P., and Boutin, J. A. (2020). Unraveling plant natural
chemical diversity for drug discovery purposes. Front. Pharmacol. 11:397. doi:
10.3389/fphar.2020.00397
Lombardino, J. G., and Lowe, J. A. III (2004). The role of the medicinal chemist
in drug discovery – then and now. Nat. Rev. Drug Discov. 3, 853–862. doi:
10.1038/nrd1523
Machado, V. R., Biavatti, M. W., and Danheiser, R. L. (2018). A short and
efficient synthesis of the polyacetylene natural product deca-4,6,8-triyn-1-ol.
Tetrahedron Lett. 59, 3405–3408. doi: 10.1016/j.tetlet.2018.07.059
Martin, E. F., Mbaveng, A. T., Moraes, M. H., Kuete, V., Biavatti, M. W.,
Steindel, M., et al. (2018). Prospecting for cytotoxic and antiprotozoal
4−aryl−4H−chromenes and 10−aryldihydropyrano[2,3−f] chromenes. Arch.
Pharm. (Weinheim) 351, 1–11. doi: 10.1002/ardp.201800100
Mbaveng, A. T., Kuete, V., Ngameni, B., Beng, V. P., Ngadjui, B. T., Meyer, J. J. M.,
et al. (2012). Antimicrobial activities of the methanol extract and compounds
from the twigs of Dorstenia mannii (Moraceae). BMC Comp. Altern. Med. 12:83.
doi: 10.1186/1472-6882-12-83
Mbaveng, A. T., Ngameni, B., Kuete, V., Simo, I. K., Ambassa, P., Roy, R., et al.
(2008). Antimicrobial activity of the crude extracts and five flavonoids from
the twigs of Dorstenia barteri (Moraceae). J. Ethnopharmacol. 116, 483–489.
doi: 10.1016/j.jep.2007.12.017
Mbaveng, A. T., Sandjo, L. P., Tankeo, S. B., Ndifor, A. R., Pantaleon, A., Nagdjui,
B. T., et al. (2015). Antibacterial activity of nineteen selected natural products
against multi-drug resistant Gram-negative phenotypes. SpringerPlus. 4, 823–
831. doi: 10.1186/s40064-015-1645-8
Mitscher, L. A., Okwute, S. K., Gollapudi, S. R., Drake, S., and Avona, E. (1988).
Antimicrobial pterocarpans of Nigerian Erythrina mildbraedii. Phytochemistry
27, 3449–3452. doi: 10.1016/0031-9422(88)80746-5
The Working Group for New TB Drugs (2020). New Drugs for TB Clinical Pipeline.
Available online at: https://www.newtbdrugs.org/pipeline/clinical (accessed
October 19, 2020).
Ngadjui, B. T., Abegaz, B. M., Dongo, E., Tamboue, H., and Fogue, S. K. (1998).
Geranylated and prenylated flavonoids from the twigs of Dorstenia mannii.
Phytochemistry 48, 349–354. doi: 10.1016/S0031-9422(97)01120-5
Pascolutti, M., and Quinn, R. J. (2014). Natural products as lead structures:
chemical transformations to create lead-like libraries. Drug Discov. Today 19,
215–221. doi: 10.1016/j.drudis.2013.10.013
Pollo, L. A. E., Moraes, M. H., Cisilotto, J., Creczynski-Pasa, T. B., Biavatti,
M. W., Steindel, M., et al. (2017). Synthesis and in vitro evaluation of Ca2+
channel blockers 1,4-dihydropyridines analogues against Trypanosoma cruzi
and Leishmania amazonensis: SAR analysis. Parasitol. Int. 66, 789–797. doi:
10.1016/j.parint.2017.08.005
Raj, L., and Lee, J. (2020). 2H/4H-Chromenes – A versatile biological attractive
scaffold. Front. Chem. 8:623. doi: 10.3389/fchem.2020.00623
Rogoza, L. N., Salakhutdinov, N. F., and Tolstikov, G. A. (2010). Antituberculosis
activity of natural and synthetic compounds. Chem. Sustain. Dev. 10, 343–375.
Salomon, C. E., and Schmidt, L. E. (2012). Natural products as leads for
tuberculosis drug development. Curr. Top. Med. Chem. 12, 735–765. doi: 10.
2174/156802612799984526
Sandjo, L. P., Kuete, V., Nana, F., Kirsch, G., and Efferth, T. (2016a). Synthesis
and cytotoxicity of 1,4-Dihydropyridines and an unexpected 1,3-Oxazin-6-one.
HelvChim. Acta 99, 310–314. doi: 10.1002/hlca.201500265
Sandjo, L. P., Moraes, M. H., Kuete, V., Kamdoum, B. C., Ngadjui, B. T., and
Steindel, M. (2016b). Individual and combined antiparasitic effect of six plant
metabolites against Leishmania amazonensis and Trypanosoma cruzi. Bioorg.
Med. Chem. Lett. 26, 1772–1775. doi: 10.1016/j.bmcl.2016.02.044
Schinkovitz, A., Stavri, M., Gibbons, S., and Bucar, F. (2008). Antimycobacterial
polyacetylenes from Levisticum officinale. Phytother. Res. 22, 681–684. doi: 10.
1002/ptr.2408
Solecki, E., and Shanidar, I. V. (1975). A Neanderthal flower burial in northern
Iraq. Science 190, 880–881. doi: 10.1126/science.190.4217.880
Somagond, S. M., Kamble, R. R., Bayannavar, P. K., Shaikh, S. K. J., Joshi, S. D.,
Kumbar, V. M., et al. (2019). Click chemistry based regioselective one-pot
synthesis of coumarin-3-yl-methyl-1,2,3-triazolyl-1,2,4-triazol-3(4H)-ones as
newer potent antitubercular agents. Arch. Pharm. (Weinheim) 352, 1–13. doi:
10.1002/ardp.201900013
Sugamoto, K., Matsusita, Y. I., Matsui, K., Kurogi, C., and Matsui, T. (2011).
Synthesis and antibacterial activity of chalcones bearing prenyl or geranyl
groups from Angelica keiskei. Tetrahedron. 67, 5346–5359. doi: 10.1016/j.tet.
2011.04.104
Teklehaymanot, T. (2009). Ethnobotanical study of knowledge and medicinal
plants use by the people in Dek Island in Ethiopia. J. Ethnopharmacol. 124,
69–78. doi: 10.1016/j.jep.2009.04.005
Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi,
A., et al. (2018). Natural products for drug discovery in the 21st century:
innovations for novel drug discovery. Int. J. Mol. Sci. 19, 1578–1606. doi: 10.
3390/ijms19061578
Togola, A., Austarheim, I., Theis, A., Diallo, D., and Paulse, B. S. (2008).
Ethnopharmacological uses of Erythrina senegalensis: a comparison of three
areas in Mali, and a link between traditional knowledge and modern
biological science. J. Ethobiol. Ethnomed. 4, 6–14. doi: 10.1186/1746-42
69-4-6
World Health Organization (2014). End TB Strategy. Geneva: WHO.
World Health Organization (2020). Global Tuberculosis Report 2020. Geneva:
WHO.
Wright, G. D. (2019). Unlocking the potential of natural products in drug
discovery. Microb. Biotechnol. 12, 55–57. doi: 10.1111/1751-7915.13351
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Pollo, Martin, Machado, Cantillon, Wildner, Bazzo, Waddell,
Biavatti and Sandjo. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 11 January 2021 | Volume 11 | Article 622629
